Business Wire·Sep 9, 2026, 8:00 AM ET

Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer

TTRX

Turn Therapeutics Inc. appointed Robert R. Redfield, M.D., as Chief Scientific Officer.
Dr. Redfield brings over four decades of experience in immunology, microbiology, infectious disease, clinical research, & public health.
His scientific literature has been cited more than 35,000 times, focusing on cytokine signaling & host-pathogen interactions.
He previously served as the 18th Director of the U.S. Centers for Disease Control and Prevention from 2018 to 2021.
Dr. Redfield spent roughly two decades in the U.S. Army Medical Corps, retiring with the rank of Colonel after conducting research at Walter Reed Army Medical Center.
He previously held leadership roles at the University of Maryland School of Medicine, including Professor of Medicine, Microbiology, & Immunology.
At Turn Therapeutics, he will guide the scientific strategy for GX-03 in atopic dermatitis, onychomycosis, hidradenitis suppurativa, & other potential indications.
His work will emphasize cytokine signaling & the host inflammatory response to microbial stimuli.
Dr. Redfield will collaborate with CEO Bradley Burnam, Executive Clinical Lead Stephen M. Hahn, & clinical investigators.
GX-03 is currently being evaluated for atopic dermatitis, with preclinical data showing effects on inflammatory mediators IL-31 & IL-36.
The company is also developing GX-03 for onychomycosis & plans to explore additional indications involving localized microbial & inflammatory processes.
Dr. Redfield earned his medical degree from Georgetown University School of Medicine.